ALS-linked FUS mutations (P525L, R521C) impair nuclear import via karyopherin-β2 (Transportin-1), causing cytoplasmic accumulation and splicing dysregulation. A compound screen for nuclear import correctors is proposed. Critical weaknesses include lack of validated small-molecule PPI modulators for FUS-Transportin-1, insufficient correlation between N/C ratio and functional splicing restoration, and stress granule pathology that may persist even with partial nuclear import restoration.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["FUS Mutation RNA-binding Protein Misfolding"]
B["Cytoplasmic Inclusion Formation"]
C["Mitochondrial Dysfunction"]
D[" oxidative Stress ROS Accumulation"]
E["NCOA4-mediated Ferritinophagy"]
F["Labile Iron Pool Expansion"]
G["Lipid Peroxidation GPX4 Overwhelmed"]
H["Ferroptotic Motor Neuron Death"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMIDValidation: 0%3 supporting / 3 opposing
✓For(3)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic Hypotheses in Neurodegeneration
Hypothesis 1: TREM2 Microglial Activation as Therapeutic Target in Alzheimer's Disease
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Neurodegeneration Therapeutic Hypotheses
Hypothesis 1: TREM2 Microglial Activation
Original Confidence: 0.78 → Revised: 0.62
Weak Links
Dose-dependency assumption unexamined. TREM2 signaling has a documented biphasic character — agonistic antibodies at high concentrations can cause receptor internalization and desensitization (Painter et al., 2018). The therapeutic window for 4D9 agonism is not established in the primary literature.
Mouse model confounding. The 5xFAD/Trem2−/− cross is problematic as a therapeutic-test platform: deleting TR
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
This assessment evaluates each hypothesis across five domains:
Druggability — tractability of the target and chemical matter
Biomarkers & Model Systems — readouts and experimental platforms available
Clinical-Development Constraints — regulatory, enrollment, and endpoint considerations
Safety — on-target and off-target liabilities
Timeline & Cost Realism — phase-appropriate milestones and resource requirements
Hypothesis 1: TREM2 Microglial Activation in AD
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD", "description": "Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsuffic